Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pediatric Rare Disease Voucher Program Faces Expiration

Sep 11 2016

• By Derrick Gingery

Priority Review Voucher

Related Content

Priority Review Vouchers, FDA Funding Win In Omnibus Budget Deal

Dec 17 2015

Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

May 27 2015

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says

Mar 03 2016

No FDA Funding Boost In Senate HELP GOP Members' Innovation Bill

Mar 14 2016

Tracking The Priority Review Vouchers

Jul 27 2016

Priority Review Vouchers Appear To Be Dropping In Price

Jul 27 2016

NIH's Zika Vaccine Faces Funding Challenge After Skipping Industry Partnership

Aug 17 2016

Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems

Aug 22 2016

GDUFA II Will Include Small Business Relief, Priority ANDA Reviews

Aug 31 2016

Related Companies

United Therapeutics Corporation

AbbVie Inc.

Gilead Sciences, Inc.

Sanofi

Novo Nordisk A/S

Travere Therapeutics, Inc.

Additional Topics

United States Review Pathway Drug Review Legislation Policy BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window